CaroGen Corporation has selected BioCentriq™ as their partner for clinical manufacturing to support Phase 1 clinical trials of its lead immunotherapy candidate, CARG-201, which has been designed to generate multiple hepatitis B virus antigens and to stimulate broad immune responses.
“We are thrilled to have received over $5 million funding from National Institute of Health to support our HBV preclinical program and have the opportunity to engage an expert and innovative partner like BioCentriq to help validate our methods, further develop our manufacturing processes and ultimately produce high-quality clinical grade materials,” said Bijan Almassian, Ph.D. and CaroGen’s co-founder and CEO.